{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wilson C"],"funding":["National Health &amp; Medical Research Council Emerging Leadership Fellowship","Liu McCabe Family Scholarship","National Health and Medical Research Council","Caroline Quinn Research Grant"],"pagination":["e064682"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9945047"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(2)"],"pubmed_abstract":["<h4>Introduction</h4>Metformin is a medication likely to improve measures of cardiometabolic disturbance in young people with mental illness. Evidence also suggests metformin may improve depressive symptoms. This 52-week double-blind randomised control trial (RCT) aims to investigate the efficacy of metformin pharmacotherapy as an adjunct to a healthy lifestyle behavioural intervention in improving cardiometabolic outcomes, and depressive, anxiety and psychotic symptoms in youth with clinically diagnosed major mood syndromes.<h4>Methods and analysis</h4>At least 266 young people aged 16-25 presenting for mental healthcare for major mood syndromes who are also at risk for poor cardiometabolic outcomes will be invited to participate in this study. All participants will engage in a 12-week sl"],"journal":["BMJ open"],"pubmed_title":["Double-blind, randomised placebo-controlled clinical trial of metformin as an adjunct to a sleep-wake, activity and metabolically focused behavioural intervention to improve cardiometabolic outcomes and mood symptoms in youth with major mood syndromes: study protocol."],"pmcid":["PMC9945047"],"funding_grant_id":["awarded to CW","awarded to J.J.C","511921, awarded to I.B.H","awarded to JSC"],"pubmed_authors":["Song YJC","Wilson C","Crouse J","Hickie IB","Scott EM","McHugh C","Hamilton B","Carpenter JS","Zmicerevska N","Nichles A","Koethe D","Hockey S"],"additional_accession":[]},"is_claimable":false,"name":"Double-blind, randomised placebo-controlled clinical trial of metformin as an adjunct to a sleep-wake, activity and metabolically focused behavioural intervention to improve cardiometabolic outcomes and mood symptoms in youth with major mood syndromes: study protocol.","description":"<h4>Introduction</h4>Metformin is a medication likely to improve measures of cardiometabolic disturbance in young people with mental illness. Evidence also suggests metformin may improve depressive symptoms. This 52-week double-blind randomised control trial (RCT) aims to investigate the efficacy of metformin pharmacotherapy as an adjunct to a healthy lifestyle behavioural intervention in improving cardiometabolic outcomes, and depressive, anxiety and psychotic symptoms in youth with clinically diagnosed major mood syndromes.<h4>Methods and analysis</h4>At least 266 young people aged 16-25 presenting for mental healthcare for major mood syndromes who are also at risk for poor cardiometabolic outcomes will be invited to participate in this study. All participants will engage in a 12-week sl","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T18:59:44.146Z","creation":"2025-04-04T18:59:44.146Z"},"accession":"S-EPMC9945047","cross_references":{"pubmed":["36810174"],"doi":["10.1136/bmjopen-2022-064682"]}}